Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipatasertib + rucaparib
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ipatasertib + rucaparib is a combination of two small molecule drugs being evaluated for the treatment of advanced cancers, particularly metastatic castration-resistant prostate cancer (mCRPC), and also in advanced breast and ovarian cancer. Ipatasertib is an AKT inhibitor that targets the serine/threonine kinase AKT, part of the PI3K/AKT signaling pathway, which is frequently dysregulated in tumors. Rucaparib is a PARP inhibitor that targets poly(ADP-ribose) polymerase enzymes (mainly PARP1, PARP2), which are involved in DNA repair. This combination is designed to leverage potential synthetic lethality in tumors with homologous recombination deficiencies or PTEN loss, but Phase Ib studies have shown that while the regimen is tolerable, it does not demonstrate clear synergistic or additive antitumor activity in mCRPC patients previously treated with androgen receptor inhibitors[1][2][3][4][5].
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)PARP3 (Poly(adp-ribose) polymerase 3)Pol II (RNA polymerase II elongation factors)
Beyond the preview
Go deeper on ipatasertib + rucaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipatasertib + rucaparib.